Peptilogics

Peptilogics is an early stage biotech developing a breakthrough technology platform in the antimicrobial segment.

Peptilogics is developing eCAP technology, a propriety platform with preclinical effectiveness against resistant bacteria and biofilms. The company is dedicated to developing a new class of broad-spectrum antibiotics to address the epidemic of multidrug-resistant bacterial infections. Peptilogics is a preclinical biotechnology company with demonstrated preclinical in vitro and in vivo effectiness against the priority resistant pathogens.